Drug Pricing
Drug Pricing
Advancing Innovation and Access
We analyze the value that therapies bring to patients and develop novel payment models for rewarding innovation while restraining costs.
Featured Article
A Patient-Focused, Evidence-Driven Approach to PBM Reform
Patients and consumers bear the costs of an inefficient pharmaceutical distribution system through higher costs at the pharmacy counter and reduced access to critical therapies. As policymakers consider reforms to the drug supply chain, they should keep five principles in mind to ensure better outcomes for patients.
Karen Van Nuys, Dana Goldman, Stephanie Hedt, Geoffrey Joyce, Darius Lakdawalla, Barry Liden, Neeraj Sood, Erin Trish
White Paper
Mitigating the IRA’s Adverse Impacts on the Prescription Drug Market
Although the Inflation Reduction Act of 2022 (IRA) aimed to increase patient access to prescription drugs and decrease spending, researchers warn that it may have unintended negative impacts on patients in the long run. A Schaeffer Center white paper recommends three strategies to mitigate adverse impacts of the IRA.
Read the White PaperLatest Research
